Pulmatrix, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
PULM Nasdaq 2836 www.pulmatrix.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Pulmatrix, Inc.

Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets - May 15th, 2025 6:05 am
Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets - Mar 21st, 2025 6:05 am
Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain - Jan 22nd, 2025 6:00 am
Pulmatrix and Cullgen Announce Proposed Merger - Nov 13th, 2024 7:00 am
Pulmatrix Third Quarter 2024 Earnings: US$0.71 loss per share (vs US$1.03 loss in 3Q 2023) - Nov 10th, 2024 5:07 am
Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Nov 8th, 2024 8:26 am
Pulmatrix Second Quarter 2024 Earnings: US$1.59 loss per share (vs US$1.05 loss in 2Q 2023) - Aug 15th, 2024 4:30 am
Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update - Aug 13th, 2024 7:05 am